Trials: Phase 1

You are here:

Find a Clinical Trial
Phase 1

NCT04794699 – An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) in Adult Participants with Advanced Solid Tumors

October 30, 2025

NCT05023486 – NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

October 30, 2025

NCT05548296 – A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

October 30, 2025

NCT05675449 – A Phase 1B, Open-label Study of Elranatamab in Combination with Carfilzomib Plus Dexamethasone and Elranatamab in Combination with PF-07901801 in Participants with Relapsed Refractory Multiple Myeloma

October 30, 2025

NCT06253130 – A First-In-Human, Phase 1/2, Open-Label, Multi-Center, Dose-Escalation, Dose-Optimization, and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy and in Combination in Participants with Advanced Solid Tumors

August 12, 2025

NCT06313502 – High dose ascorbic acid (HDAA) in patients with plasma cell disorders

January 8, 2026

NCT06313502 – High dose ascorbic acid (HDAA) in patients with plasma cell disorders

January 8, 2026

NCT06515613 – A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors

October 30, 2025